A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Completed · Phase 3 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).

Key facts

Study ID
NCT03525444
Run by
Vertex Pharmaceuticals Incorporated
People needed
405
Starts
2018-06-15
Expected to finish
2019-04-24
Last updated by the study team
2020-05-19

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.